ALRN
had some weekend news. Will be interesting to see if it can break above a near-two-year resistance level. I didn't show it all the way back to November of 2018 but if you take the chart out further, you can see this level holding as resistance. "Saturday, the company announced new positive clinical data from its ongoing Phase 1b trial. The trial demonstrated clinical proof of concept that treatment with ALRN-6924 prior to second-line topotecan administration resulted in a protective effect against severe anemia, thrombocytopenia and neutropenia. This was in patients with p53-mutated small cell lung cancer. The results were featured in a late-breaking poster presentation entitled, 'Prevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with Dual MDM2/MDMX Inhibitor ALRN-6924.'"
Original Quote Source: 5 Penny Stocks On Robinhood To Buy Under $2; Are They Too Risky?